Policy

Health Plans Continue to Seek Methods to Curtail Cancer Costs

Bimal Patel, PharmD, MS, Director, Health Outcomes Research, MedImpact Healthcare Systems, Inc., discusses MedImpact's work to identify, analyze, and evaluate generic medications that have become significantly expensive, and effective strategies for managing these costs.

To set priorities for quality improvement in trauma triage, we compared the cost-effectiveness of current practice with interventions to improve physician adherence to clinical guidelines.

Hospital readmission rates in Medicare Advantage plans are considerably lower than those in Medicare's traditional fee-for-service program, after accounting for differences in risk.

Analysis of studies of worksite wellness programs suggested mixed impact on health-related behaviors and cost, with insufficient evidence regarding absenteeism and mental health.

Use of granulocyte colony-stimulating factor plus plerixafor for stem cell mobilization is cost-effective in pretreated patients with non-Hodgkin lymphoma.

In this systematic review and meta-analysis, we found that hospitalists reduce hospital length of stay without increasing costs.

Higher patient cost-sharing is associated with a lower likelihood of treatment augmentation in patients with depression who are treated with antidepressants.

An insurance benefit that provides percutaneous coronary intervention patients with a discharge supply of antiplatelet medication could result in cost savings for insurers.

Costs of potentially avoidable complications have significantly more variation than costs of typical care in selected chronic and procedural episodes.

As the FDA continues to work on the biosimilars approval process, there are growing concerns that a true cost-savings can't be realized.

Dr. Jonathan Meyer discusses the importance of prescribing the most appropriate medications for schizophrenia patients.

Healthcare costs are elevated for patients on chronic opioid therapy; nonadherence to the opioid regimen, based on urine drug monitoring results, further increases costs.